CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 100.0%

Compliant submissions 1

Incompliant submissions 0

Total trials 1

My Organizations' Clinical Trials

Showing 50 of 279 entries

View as:

Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy

Phase: N/A Priority: Normal

NCT ID: NCT03728699 Org: User:

Start: 01/02/18 End: 02/18/22 Due: 02/18/23

Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation

Phase: N/A Priority: Normal

NCT ID: NCT02074631 Org: User:

Start: 02/28/15 End: 10/06/22 Due: 10/06/23

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

Phase: N/A Priority: Normal

NCT ID: NCT00309842 Org: User:

Start: 07/28/05 End: 11/22/19 Due: 11/22/20

Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study

Phase: N/A Priority: Normal

NCT ID: NCT01705288 Org: User:

Start: 01/01/13 End: 08/24/16 Due: 08/24/17

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

Phase: N/A Priority: Normal

NCT ID: NCT04466098 Org: User:

Start: 07/30/20 End: 12/31/24 Due: 12/31/25

Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer

Phase: N/A Priority: Normal

NCT ID: NCT01560923 Org: User:

Start: 10/01/12 End: 12/12/18 Due: 12/12/19

Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

Phase: N/A Priority: Normal

NCT ID: NCT01581970 Org: User:

Start: 06/30/12 End: 09/30/15 Due: 09/30/16

Feasibility Study - Filter Ventilation

Phase: N/A Priority: Normal

NCT ID: NCT04514471 Org: User:

Start: 03/18/24 End: 07/31/26 Due: 07/31/27

Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia

Phase: N/A Priority: Normal

NCT ID: NCT00005984 Org: User:

Start: 08/31/00 End: 09/30/05 Due: 09/30/06

Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure

Phase: N/A Priority: Normal

NCT ID: NCT03998735 Org: User:

Start: 10/19/21 End: 10/31/26 Due: 10/31/27

Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Phase: N/A Priority: Normal

NCT ID: NCT01312818 Org: User:

Start: 06/30/11 End: 01/31/13 Due: 01/31/14

Role of Acetaldehyde in the Development of Oral Cancer

Phase: N/A Priority: Normal

NCT ID: NCT05973656 Org: User:

Start: 07/08/22 End: 09/30/27 Due: 09/30/28

Tobacco Constituents and Biomarkers

Phase: N/A Priority: Normal

NCT ID: NCT04090606 Org: User:

Start: 12/31/13 End: 03/22/21 Due: 03/22/22

Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy

Phase: N/A Priority: Normal

NCT ID: NCT06414278 Org: User:

Start: 02/08/24 End: 02/21/28 Due: 02/21/29

Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome

Phase: N/A Priority: Normal

NCT ID: NCT02156674 Org: User:

Start: 01/26/16 End: 12/01/19 Due: 12/01/20

Charcoal in Lung Cancer Patients Undergoing TEMLA

Phase: N/A Priority: Normal

NCT ID: NCT04928950 Org: User:

Start: 01/26/22 End: 01/31/25 Due: 01/31/26

Telehealth-Filter Ventilation ( COMET2P1 )

Phase: N/A Priority: Normal

NCT ID: NCT04969783 Org: User:

Start: 05/26/21 End: 03/21/24 Due: 03/21/25

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Phase: N/A Priority: Normal

NCT ID: NCT04105270 Org: User:

Start: 11/30/22 End: 01/31/28 Due: 01/31/29

MRI in Predicting Tumor Reponse After Radiofrequency Ablation in Women With Invasive Breast Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00373152 Org: User:

Start: 03/31/05 End: 06/30/10 Due: 06/30/11

Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00287885 Org: User:

Start: 03/31/04 End: 12/31/08 Due: 12/31/09

FT516 and IL2 With Enoblituzumab for Ovarian Cancer

Phase: N/A Priority: Normal

NCT ID: NCT04630769 Org: User:

Start: 04/02/21 End: 01/01/22 Due: 01/01/23

Stem Cell Transplant for Hemoglobinopathy

Phase: N/A Priority: Normal

NCT ID: NCT00176852 Org: User:

Start: 06/30/02 End: 01/31/20 Due: 01/31/21

Allogeneic Transplantation For Severe Osteopetrosis

Phase: N/A Priority: Normal

NCT ID: NCT00775931 Org: User:

Start: 08/31/08 End: 06/30/13 Due: 06/30/14

QuitGuide for American Indians: Aims 2 & 3

Phase: N/A Priority: Normal

NCT ID: NCT05447156 Org: User:

Start: 12/14/22 End: 11/29/23 Due: 11/29/24

Adrenoleukodystrophy National Registry Study

Phase: N/A Priority: Normal

NCT ID: NCT03789721 Org: User:

Start: 05/01/19 End: 02/28/30 Due: 02/28/31

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy	NCT03728699	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2018-01-02	2022-02-18	2023-02-18	-	-	2025-07-14
Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation	NCT02074631	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2015-02-28	2022-10-06	2023-10-06	-	-	2025-07-14
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases	NCT00309842	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2005-07-28	2019-11-22	2020-11-22	-	-	2025-07-14
Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study	NCT01705288	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2013-01-01	2016-08-24	2017-08-24	-	-	2025-07-14
Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)	NCT04466098	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2020-07-30	2024-12-31	2025-12-31	-	-	2025-07-14
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer	NCT01560923	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2012-10-01	2018-12-12	2019-12-12	-	-	2025-07-14
Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer	NCT01581970	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2012-06-30	2015-09-30	2016-09-30	-	-	2025-07-14
Feasibility Study - Filter Ventilation	NCT04514471	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2024-03-18	2026-07-31	2027-07-31	-	-	2025-07-14
Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia	NCT00005984	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2000-08-31	2005-09-30	2006-09-30	-	-	2025-07-14
Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure	NCT03998735	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2021-10-19	2026-10-31	2027-10-31	-	-	2025-07-14
Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)	NCT01312818	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2011-06-30	2013-01-31	2014-01-31	-	-	2025-07-14
Role of Acetaldehyde in the Development of Oral Cancer	NCT05973656	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2022-07-08	2027-09-30	2028-09-30	-	-	2025-07-14
Tobacco Constituents and Biomarkers	NCT04090606	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2013-12-31	2021-03-22	2022-03-22	-	-	2025-07-14
Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy	NCT06414278	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2024-02-08	2028-02-21	2029-02-21	-	-	2025-07-14
Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome	NCT02156674	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2016-01-26	2019-12-01	2020-12-01	-	-	2025-07-14
Charcoal in Lung Cancer Patients Undergoing TEMLA	NCT04928950	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2022-01-26	2025-01-31	2026-01-31	-	-	2025-07-14
Telehealth-Filter Ventilation ( COMET2P1 )	NCT04969783	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2021-05-26	2024-03-21	2025-03-21	-	-	2025-07-14
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial	NCT04105270	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2022-11-30	2028-01-31	2029-01-31	-	-	2025-07-14
MRI in Predicting Tumor Reponse After Radiofrequency Ablation in Women With Invasive Breast Cancer	NCT00373152	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2005-03-31	2010-06-30	2011-06-30	-	-	2025-07-14
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer	NCT00287885	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2004-03-31	2008-12-31	2009-12-31	-	-	2025-07-14
FT516 and IL2 With Enoblituzumab for Ovarian Cancer	NCT04630769	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2021-04-02	2022-01-01	2023-01-01	-	-	2025-07-14
Stem Cell Transplant for Hemoglobinopathy	NCT00176852	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2002-06-30	2020-01-31	2021-01-31	-	-	2025-07-14
Allogeneic Transplantation For Severe Osteopetrosis	NCT00775931	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2008-08-31	2013-06-30	2014-06-30	-	-	2025-07-14
QuitGuide for American Indians: Aims 2 & 3	NCT05447156	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2022-12-14	2023-11-29	2024-11-29	-	-	2025-07-14
Adrenoleukodystrophy National Registry Study	NCT03789721	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2019-05-01	2030-02-28	2031-02-28	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance